Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

8 Apr 2025 07:00

RNS Number : 9913D
Intercede Group PLC
08 April 2025
Β 

Β 

Β 

8 April 2025

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Trading Update

Intercede, the leading cybersecurity software company specialising in digital identities, today announces the following trading update for the financial year ending 31 March 2025 (FY25).

As highlighted in the announcements dated 8 January 2025, 12 March 2025 and 2 April 2025, Intercede's underlying trading performance has continued to show strong momentum for the year, compared to market forecasts. The Group is pleased to announce that, subject to the completion of the year end audit, revenues for FY25 are expected to be approximately Β£17.7m (2024: Β£20m), 11.4% lower than FY24, with the previous year benefiting from an exceptional perpetual licence and associated support and maintenance order of cΒ£6.3m. The Group's revenues are 9.6% lower on a constant currency basis. Recurring support & maintenance and subscription revenues of cΒ£10.2m represented c58% of total revenues, reflecting the continued progress in licence wins and low churn rates.

Β 

The combination of strong revenues and high operational gearing is expected to result in improved forecasted profitability, subject to completion of the year end audit.

Β 

As at 31 March 2025, gross cash balances totalled Β£18.7m (2024: Β£17.2m), even after the Group had exceptional cash outflows of cΒ£0.9m, relating to Share Buy Backs (Β£0.42m) and change in R&D tax election resulting in a repayment of Β£0.44m from the FY23 R&D cash claim and foregoing a FY24 forecasted R&D cash claim of cΒ£0.5m-Β£0.6m. The key purpose for the R&D tax election change is to ulitise R&D expense deductions against the Group's future taxable profits. The Group has no debt.

Β 

Further details will be provided within Intercede's final preliminary results which are expected to be published in June 2025.

Β 

Β 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

Β 

Β 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Marc Milmo/Fergus Sullivan/Rory Sale

Corporate Finance

Tim Redfern/Ondraya Swanson

ECM

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Β 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

Β 

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI.Β Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and custom development capabilities as well as managing the world's largest password breach database.

Β 

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTSSSFMWEISEFL
Date   Source Headline
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.